Moreover, integrating other immunomodulatory agents, like CD73 inhibitors, may further enhance the efficacy of DLL3-targeted therapies by mitigating immune suppression in the SCLC microenvironment. This evidence concerns the gene DLL3 and small cell lung carcinoma.